Table 3. Prognostic assessments.
| Variable | No (%) |
|---|---|
| MSKCC risk groups (n=305) | |
| Good prognosis | 7 (1.3) |
| Intermediate prognosis | 153 (28.0) |
| Poor prognosis | 145 (26.5) |
| Unknown | 242 (44.2) |
| Risk groups according to Hudes (n=187) | |
| Non-poor prognosis | 40 (7.3) |
| Poor prognosis | 147 (26.9) |
| Unknown | 360 (65.8) |
| IMDC risk groups (n=248) | |
| Good prognosis | 8 (1.5) |
| Intermediate prognosis | 95 (17.4) |
| Poor prognosis | 145 (26.5) |
| Unknown | 299 (54.7) |
| Subjective prognostic assessment by physician before therapy (n=530) | |
| Good | 50 (9.1) |
| Intermediate | 197 (36.0) |
| Poor | 283 (51.7) |
| Unknown | 17 (3.1) |
No, number; MSKCC, Memorial Sloan-Kettering Cancer Center prognostic score; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium risk score.